
The rise of pills marketed for women’s confidence reveals the intersection of gender, medicine, capitalism, and the unfinished politics of liberation.
Confidence has long been a contested resource. For men, it is assumed; for women, it is prescribed. Across the twentieth century, women fought for the right to vote, to work, to control their bodies. By the twenty-first, another frontier emerged: the right to feel adequate in a world designed to diminish them. Now, in 2025, a pill promises to deliver what centuries of social conditioning have withheld—confidence. Marketed as a biochemical shortcut to self-assurance, it is the latest emblem of how gender, medicine, and capitalism intersect. But what does it mean when confidence itself is commodified? And why does the demand for such a pill tell us more about society’s failures than women’s shortcomings?
This is not simply a story about pharmacology. It is about power.
To understand the confidence pill, one must trace the lineage of how medicine has historically framed women. From “hysteria” in the nineteenth century to Prozac in the 1990s, the female body has been treated as a site of correction. Pills have been prescribed not only to treat illness but to manage behaviour, to conform women to systems never built for them. The contraceptive pill in the 1960s was revolutionary—granting women unprecedented control over reproduction. Yet even that liberation was framed within male-dominated institutions of science and commerce. The confidence pill is the latest iteration. It suggests that rather than dismantling systems that erode women’s self-assurance, society will provide capsules to compensate. The body must adapt, not the culture.
Pharmacologically, the pill in question combines mild stimulants with mood regulators designed to enhance dopamine and serotonin levels. Scientifically, it is not radically different from existing antidepressants or anti-anxiety medication. The difference lies in branding. It is sold not as treatment but as enhancement. Not as therapy but as empowerment. Glossy advertisements promise not relief from disorder but the arrival of confidence itself: “Be Bold. Be Fearless. Be You—Now in One Dose.” This reframing is crucial. The pharmaceutical industry has realised that aspiration sells better than pathology. Confidence is marketable. And in a culture saturated with self-help rhetoric, the promise of instant self-belief is irresistible.
The confidence pill thrives because capitalism excels at turning insecurity into profit. Beauty standards, workplace hierarchies, and social expectations generate the very anxieties that pills then claim to solve. A woman underpaid compared to male colleagues may feel inadequate. Rather than reform wage structures, society offers her a pill. A teenager pressured by Instagram perfection may feel inferior. Rather than regulate platforms, society offers her a capsule. The confidence pill is thus less about empowerment than about adaptation. It allows women to cope with unjust systems rather than transform them. In this sense, it is not liberation but pacification dressed as progress.
Confidence itself is complex. It is not merely biochemical. It is relational, social, cultural. It arises from recognition, opportunity, and respect. To suggest it can be swallowed is to reduce it to chemistry alone. Yet the appeal is undeniable. Confidence is currency in workplaces, in politics, in relationships. Women denied it structurally are understandably drawn to any means of levelling the field. The pill offers not only dopamine but hope.
But hope mediated through pharmacology is fragile. What happens when the pill wears off? What happens when reliance replaces resilience Feminist scholars are divided. Some argue that the confidence pill, like the contraceptive pill before it, expands agency. Women should have the choice to alter their neurochemistry if it empowers them. Others counter that it medicalises social injustice, making women responsible for overcoming barriers that society should dismantle. The ethical debate is profound. Does empowerment through chemistry reinforce the very systems it seeks to escape? Or is every tool valid in the fight for agency? The answer may be both. Liberation is rarely pure. Tools can be co-opted even as they empower.
Nowhere is the confidence pill more evident than in the workplace. Surveys show women increasingly turn to enhancement drugs before major presentations, interviews, or negotiations. Employers, often quietly complicit, benefit from the performance boost without addressing structural inequities. The risk is clear: confidence becomes another metric of productivity, another resource to be optimised. The woman who refuses the pill may be seen as lacking drive. Enhancement becomes expectation. Choice becomes coercion. In this way, the pill risks reproducing the very inequities it claims to remedy.
The phenomenon is not confined to America. In Asia, pills marketed for confidence blur with supplements promising beauty and slimness. In Europe, debates rage over whether such pills should be regulated as medicine or lifestyle products. In Africa and Latin America, access disparities highlight the global inequality of pharmacological empowerment. The global market for “confidence enhancers” is projected to reach billions. But access is stratified. Privileged women may buy empowerment in capsules. Marginalised women remain excluded, reinforcing the hierarchies of class and race. The confidence pill is part of a broader trend of human enhancement. Nootropics for focus, stimulants for productivity, psychedelics for creativity—the body is increasingly seen as a site of optimisation.
The danger is that humanity begins to outsource identity to chemistry. If confidence, creativity, and resilience are all medicated, what remains of the unaltered self? What happens to societies that demand perpetual enhancement? The risk is not only addiction to substances but addiction to the very idea that identity must be engineered to fit capitalism’s demands.
The pill women are taking for confidence matters not because it is revolutionary medicine, but because it symbolises a deeper crisis. It reveals a society more willing to prescribe adaptation than pursue justice. It shows how capitalism commodifies even the most intimate of human traits. It underscores how gendered inequities persist, repackaged as empowerment. This still matters because confidence should not be a pill. It should be a birthright of dignity, opportunity, and equality. Until society confronts the systems that erode women’s self-assurance, no capsule can deliver true empowerment. The question is not whether women should take the pill. The question is why society keeps forcing them to.
Anonymous is a private guest contributor of WTM MEDIA. Through Why These Matter, they examines the intersections of medicine, healthcare, and design—bringing clarity to issues that shape people, influence culture, and determine the future of global society.

For most of aviation history, human flight has required an aircraft: a machine large enough to generate lift, carry fuel, accommodate passengers, and surround its occupants with an engineered structure. Emerging personal-flight technologies are beginning to loosen that relationship. Jet suits, powered wings, compact electric vertical-lift systems, autonomous drones, and increasingly sophisticated flight-control technologies suggest that aviation may eventually encompass machines worn, mounted, or summoned rather than conventionally boarded. The viral spectacle is irresistible. A person rises from the ground, accelerates over water, and appears to have acquired a superpower. Yet spectacle obscures the engineering. Human-scale powered flight confronts brutal constraints involving energy density, heat, noise, stability, endurance, payload, weather, redundancy, training, regulation, and the consequences of mechanical failure. A technology can fly successfully and still be unsuitable for mass transportation. That distinction is central to understanding personal aviation. The most plausible near-term applications are unlikely to involve commuters casually flying between homes and offices. Specialist environments — emergency response, defence, offshore infrastructure, inaccessible terrain, inspection, rescue, and certain industrial operations — provide a more credible pathway because the economic value of reaching somewhere quickly can outweigh the technology’s considerable limitations. The deeper development, however, extends beyond jet suits. Aviation is becoming computational. Sensors can stabilise machines faster than human reflexes. Software can continuously adjust thrust. Lightweight materials reduce mass. Autonomous navigation increasingly separates piloting from constant manual control. Electric propulsion enables aircraft configurations that would have been impractical under traditional mechanical architectures. The result is not necessarily the death of the aeroplane. Commercial aircraft remain extraordinarily efficient at moving large numbers of people over long distances. Instead, aviation may be fragmenting into a richer ecosystem: aircraft for distance, drones for autonomous logistics, eVTOL systems for specialised regional movement, and wearable or highly compact systems for particular human-scale missions. The important question is therefore no longer simply, “Can a person fly without an aeroplane?” We already know that certain machines can make that possible. The better question is: when does removing the aircraft make flight more useful?

Canada’s Medical Assistance in Dying programme has moved an ancient human question into modern medicine: when suffering becomes intolerable, who should have authority over how life ends? In 2024, 16,499 people received MAID—5.1 per cent of deaths in Canada. Yet the headline conceals crucial distinctions: 95.6 per cent were people whose natural deaths were reasonably foreseeable; 4.4 per cent were not. Most recipients had received palliative care, while disability advocates, clinicians, ethicists and policymakers continue to dispute whether safeguards can adequately separate autonomous choice from suffering intensified by inadequate social support. The future makes the question harder. Medicine is simultaneously extending life, managing once-fatal disease, expanding organ transplantation and developing technologies that could prolong healthy longevity. A civilisation capable of keeping people alive for longer must therefore become equally sophisticated about what makes continued life worth living. The central question is larger than MAID: can a society protect the right to choose death without allowing failures of care to narrow the possibility of choosing life?

For four decades, the central challenge of HIV medicine has been control. Antiretroviral therapy can suppress the virus so effectively that people living with HIV can lead long, healthy lives and, when viral load remains undetectable, do not transmit HIV sexually. Yet treatment does not remove the latent viral reservoir embedded within the body, meaning therapy usually must continue. A developing body of HIV research is asking a different question: rather than continually suppressing an active virus, could medicine make its hidden genetic machinery remain silent? A 2025 Science Advances study found that an HIV-derived antisense transcript known as AST could reinforce viral latency in cells from people receiving treatment. Subsequent research confirmed that HIV antisense transcripts occur naturally in people living with the virus. These findings do not constitute an HIV cure. They reveal something potentially more consequential: another biological mechanism that scientists may eventually learn to manipulate. The larger intelligence is about where medicine may be heading—from repeatedly controlling disease towards redesigning the conditions that allow disease to persist.